Yijuang Chern

List of Publications by Citations

100 papers	3,822 citations	38 h-index	58 g-index
101 ext. papers	4,291 ext. citations	6.5 avg, IF	5.21 L-index

#	Paper	IF	Citations
100	Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. *Journal of Cell Biology*, **2011**, 194, 209-27	7.3	149
99	A critical role of astrocyte-mediated nuclear factor-B-dependent inflammation in Huntington's disease. *Human Molecular Genetics*, **2013**, 22, 1826-42	5.6	147
98	Aspects of the general biology of adenosine A2A signaling. *Progress in Neurobiology*, **2007**, 83, 263-76	10.9	146
97	CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. *Journal of Neurochemistry*, **2005**, 93, 310-20	6	145
96	Mutations in the ubiquitin-binding domain of OPTN/optineurin interfere with autophagy-mediated degradation of misfolded proteins by a dominant-negative mechanism. *Autophagy*, **2015**, 11, 685-700	10.2	95
95	Protein kinase C inhibits adenylyl cyclase type VI activity during desensitization of the A2a-adenosine receptor-mediated cAMP response. *Journal of Biological Chemistry*, **1997**, 272, 4970-7	5.4	95
94	Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. *Journal of Neuroscience*, **2008**, 28, 3277-90	6.6	91
93	Adenosine receptor neurobiology: overview. *International Review of Neurobiology*, **2014**, 119, 1-49	4.4	81
92	Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington's disease. *Nature Communications*, **2019**, 10, 3473	17.4	78
91	Activation of protein kinase A and atypical protein kinase C by A(2A) adenosine receptors antagonizes apoptosis due to serum deprivation in PC12 cells. *Journal of Biological Chemistry*, **2001**, 276, 13838-46	5.4	78
90	Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models. *PLoS ONE*, **2011**, 6, e22924	3.7	77
89	Essential role of cAMP-response element-binding protein activation by A2A adenosine receptors in rescuing the nerve growth factor-induced neurite outgrowth impaired by blockage of the MAPK cascade. *Journal of Biological Chemistry*, **2002**, 277, 33930-42	5.4	76
88	cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. *Journal of Biological Chemistry*, **2005**, 280, 14331-40	5.4	75
87	Spt4 is selectively required for transcription of extended trinucleotide repeats. *Cell*, **2012**, 148, 690-701	56.2	73
86	Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease. *Human Molecular Genetics*, **2007**, 16, 483-98	5.6	73
85	Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma. *Human Molecular Genetics*, **2010**, 19, 4043-58	5.6	71
84	Regulation of adenylyl cyclase in the central nervous system. *Cellular Signalling*, **2000**, 12, 195-204	4.9	71

83	PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease. *Neurobiology of Disease*, **2012**, 45, 322-8	7.5	70
82	Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease. *Human Molecular Genetics*, **2014**, 23, 4328-44	5.6	69
81	The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system. *Human Molecular Genetics*, **2009**, 18, 2929-42	5.6	68
80	A new drug design targeting the adenosinergic system for Huntington's disease. *PLoS ONE*, **2011**, 6, e20934	3.7	67
79	Neuroprotective principles from Gastrodia elata. *Journal of Natural Products*, **2007**, 70, 571-4	4.9	67
78	Molecular cloning of a novel adenosine receptor gene from rat brain. *Biochemical and Biophysical Research Communications*, **1992**, 185, 304-9	3.4	63
77	Neurovascular abnormalities in humans and mice with Huntington's disease. *Experimental Neurology*, **2013**, 250, 20-30	5.7	59
76	Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies. *Handbook of Experimental Pharmacology*, **2011**, 267-310	3.2	58
75	Aberrant astrocytes impair vascular reactivity in Huntington disease. *Annals of Neurology*, **2015**, 78, 178-92	9.4	54
74	Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease. *Human Molecular Genetics*, **2015**, 24, 1602-16	5.6	52
73	Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease. *Molecular and Cellular Biology*, **2013**, 33, 1073-84	4.8	51
72	Characterization of the rat A2A adenosine receptor gene: a 4.8-kb promoter-proximal DNA fragment confers selective expression in the central nervous system. *European Journal of Neuroscience*, **2003**, 18, 1786-96	3.5	51
71	Rescue of p53 blockage by the A(2A) adenosine receptor via a novel interacting protein, translin-associated protein X. *Molecular Pharmacology*, **2006**, 70, 454-66	4.3	50
70	AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2014**, 1842, 1668-80	6.9	49
69	The N terminus domain of type VI adenylyl cyclase mediates its inhibition by protein kinase C. *Molecular Pharmacology*, **1999**, 56, 644-50	4.3	46
68	Elucidating the role of the A2A adenosine receptor in neurodegeneration using neurons derived from Huntington's disease iPSCs. *Human Molecular Genetics*, **2015**, 24, 6066-79	5.6	45
67	Activation of AMP-activated protein kinase α1 mediates mislocalization of TDP-43 in amyotrophic lateral sclerosis. *Human Molecular Genetics*, **2015**, 24, 787-801	5.6	45
66	Beneficial Effect of a Selective Adenosine A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer's Disease. *Frontiers in Molecular Neuroscience*, **2018**, 11, 235	6.1	45

65	Targeting glial cells to elucidate the pathogenesis of Huntington's disease. *Molecular Neurobiology*, **2010**, 41, 248-55	6.2	44
64	Inhibition of catecholamine secretion from bovine chromaffin cells by adenine nucleotides and adenosine. *Journal of Neurochemistry*, **1987**, 48, 1573-6	6	42
63	Adenosine receptors activate adenylate cyclase and enhance secretion from bovine adrenal chromaffin cells in the presence of forskolin. *Journal of Neurochemistry*, **1988**, 50, 1484-93	6	41
62	AMPK-mediated regulation of neuronal metabolism and function in brain diseases. *Journal of Neurogenetics*, **2015**, 29, 50-8	1.6	38
61	Regulation of type VI adenylyl cyclase by Snapin, a SNAP25-binding protein. *Journal of Biological Chemistry*, **2004**, 279, 46271-9	5.4	37
60	Effects on murine behavior and lifespan of selectively decreasing expression of mutant huntingtin allele by supt4h knockdown. *PLoS Genetics*, **2015**, 11, e1005043	6	36
59	Dendritic trafficking of brain-derived neurotrophic factor mRNA: regulation by translin-dependent and -independent mechanisms. *Journal of Neurochemistry*, **2011**, 116, 1112-21	6	34
58	Adenosine Augmentation Evoked by an ENT1 Inhibitor Improves Memory Impairment and Neuronal Plasticity in the APP/PS1 Mouse Model of Alzheimer's Disease. *Molecular Neurobiology*, **2018**, 55, 8936-8952	6.2	32
57	Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease. *Journal of Clinical Investigation*, **2011**, 121, 1519-23	15.9	32
56	Expression of type VI adenylyl cyclase in the central nervous system: implication for a potential regulator of multiple signals in different neurotransmitter systems. *FEBS Letters*, **1998**, 436, 92-8	3.8	32
55	Protein kinase C inhibits type VI adenylyl cyclase by phosphorylating the regulatory N domain and two catalytic C1 and C2 domains. *Journal of Biological Chemistry*, **2002**, 277, 15721-8	5.4	32
54	The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2011**, 1812, 1111-20	6.9	31
53	Aberrant activation of AMP-activated protein kinase contributes to the abnormal distribution of HuR in amyotrophic lateral sclerosis. *FEBS Letters*, **2015**, 589, 432-9	3.8	29
52	Adenosine receptors and Huntington's disease. *International Review of Neurobiology*, **2014**, 119, 195-232	4.4	28
51	N-glycosylation and residues Asn805 and Asn890 are involved in the functional properties of type VI adenylyl cyclase. *Journal of Biological Chemistry*, **2001**, 276, 35450-7	5.4	28
50	Systematic uncovering of multiple pathways underlying the pathology of Huntington disease by an acid-cleavable isotope-coded affinity tag approach. *Molecular and Cellular Proteomics*, **2007**, 6, 781-97	7.6	27
49	Presence of Na+/Ca2+ exchange activity and its role in regulation of intracellular calcium concentration in bovine adrenal chromaffin cells. *Cell Calcium*, **1992**, 13, 99-106	4	27
48	Impaired water reabsorption in mice deficient in the type VI adenylyl cyclase (AC6). *FEBS Letters*, **2010**, 584, 2883-90	3.8	26

47	The influence of pathological mutations and proline substitutions in TDP-43 glycine-rich peptides on its amyloid properties and cellular toxicity. *PLoS ONE*, **2014**, 9, e103644	3.7	26
46	The A2A adenosine receptor is a dual coding gene: a novel mechanism of gene usage and signal transduction. *Journal of Biological Chemistry*, **2014**, 289, 1257-70	5.4	25
45	Energy dysfunction in Huntingtons disease: insights from PGC-1 AMPK, and CKB. *Cellular and Molecular Life Sciences*, **2012**, 69, 4107-20	10.3	25
44	Regulation of type V adenylate cyclase by Ric8a, a guanine nucleotide exchange factor. *Biochemical Journal*, **2007**, 406, 383-8	3.8	24
43	Targeting ENT1 and adenosine tone for the treatment of Huntingtons disease. *Human Molecular Genetics*, **2017**, 26, 467-478	5.6	23
42	Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntingtons disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2013**, 1832, 742-53	6.9	23
41	The 5Suntranslated regions of the rat A2A adenosine receptor gene function as negative translational regulators. *Journal of Neurochemistry*, **1999**, 73, 1790-8	6	22
40	Novel regulation of adenylyl cyclases by direct protein-protein interactions: insights from snapin and ric8a. *NeuroSignals*, **2009**, 17, 169-80	1.9	21
39	GSK3 negatively regulates TRAX, a scaffold protein implicated in mental disorders, for NHEJ-mediated DNA repair in neurons. *Molecular Psychiatry*, **2018**, 23, 2375-2390	15.1	20
38	Conformational switch of polyglutamine-expanded huntingtin into benign aggregates leads to neuroprotective effect. *Scientific Reports*, **2015**, 5, 14992	4.9	20
37	Design and synthesis of novel dual-action compounds targeting the adenosine A(2A) receptor and adenosine transporter for neuroprotection. *ChemMedChem*, **2011**, 6, 1390-400	3.7	20
36	Microglial Lectins in Health and Neurological Diseases. *Frontiers in Molecular Neuroscience*, **2018**, 11, 158	6.1	19
35	Type VI adenylyl cyclase regulates neurite extension by binding to Snapin and Snap25. *Molecular and Cellular Biology*, **2011**, 31, 4874-86	4.8	19
34	The A2A adenosine receptor rescues neuritogenesis impaired by p53 blockage via KIF2A, a kinesin family member. *Developmental Neurobiology*, **2010**, 70, 604-21	3.2	19
33	Neurovascular abnormalities in brain disorders: highlights with angiogenesis and magnetic resonance imaging studies. *Journal of Biomedical Science*, **2013**, 20, 47	13.3	18
32	Modulation of dopamine transporter activity by nicotinic acetylcholine receptors and membrane depolarization in rat pheochromocytoma PC12 cells. *Journal of Neurochemistry*, **1999**, 72, 2437-44	6	18
31	The adenosine A receptor agonist T1-11 ameliorates neurovisceral symptoms and extends the lifespan of a mouse model of Niemann-Pick type C disease. *Neurobiology of Disease*, **2018**, 110, 1-11	7.5	16
30	Structural role of amino acids 99-110 in recombinant human erythropoietin. *FEBS Journal*, **1991**, 202, 225-9		16

29	Adenosine A(2A) receptor up-regulates retinal wave frequency via starburst amacrine cells in the developing rat retina. *PLoS ONE*, **2014**, 9, e95090	3.7	16
28	Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease. *Neurobiology of Disease*, **2016**, 96, 47-53	7.5	15
27	A central role of TRAX in the ATM-mediated DNA repair. *Oncogene*, **2016**, 35, 1657-70	9.2	14
26	Identification of nuclear factor 1 (NF1) as a transcriptional modulator of rat A(2A) adenosine receptor. *Molecular Brain Research*, **2003**, 111, 61-73		14
25	Distribution and regulation of rab3C, a small molecular weight GTP-binding protein. *Biochemical and Biophysical Research Communications*, **1994**, 200, 1257-63	3.4	12
24	Longitudinal evaluation of an N-ethyl-N-nitrosourea-created murine model with normal pressure hydrocephalus. *PLoS ONE*, **2009**, 4, e7868	3.7	11
23	Degeneration of ipRGCs in Mouse Models of Huntington's Disease Disrupts Non-Image-Forming Behaviors Before Motor Impairment. *Journal of Neuroscience*, **2019**, 39, 1505-1524	6.6	11
22	Regulation of P-glycoprotein expression in brain capillaries in Huntington's disease and its impact on brain availability of antipsychotic agents risperidone and paliperidone. *Journal of Cerebral Blood Flow and Metabolism*, **2016**, 36, 1412-23	7.3	10
21	An important functional role of the N terminus domain of type VI adenylyl cyclase in Galphai-mediated inhibition. *Journal of Biological Chemistry*, **2004**, 279, 34440-8	5.4	10
20	Circadian rhythm in the Ca(2+)-inhibitable adenylyl activity of the rat striatum. *FEBS Letters*, **1996**, 385, 205-8	3.8	9
19	The adenosine analogue N6-L-phenylisopropyladenosine inhibits catecholamine secretion from bovine adrenal medulla cells by inhibiting calcium influx. *Journal of Neurochemistry*, **1992**, 59, 1399-404	6	9
18	Deletion of equilibrative nucleoside transporter-2 protects against lipopolysaccharide-induced neuroinflammation and blood-brain barrier dysfunction in mice. *Brain, Behavior, and Immunity*, **2020**, 84, 59-71	16.6	9
17	Energy Homeostasis and Abnormal RNA Metabolism in Amyotrophic Lateral Sclerosis. *Frontiers in Cellular Neuroscience*, **2017**, 11, 126	6.1	8
16	High Protein Diet and Huntington's Disease. *PLoS ONE*, **2015**, 10, e0127654	3.7	8
15	A novel G-binding protein, Gas-2 like 2, facilitates the signaling of the A2A adenosine receptor. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2013**, 1833, 3145-3154	4.9	7
14	Altered behavioral responses to gamma-aminobutyric acid pharmacological agents in a mouse model of Huntington's disease. *Movement Disorders*, **2017**, 32, 1600-1609	7	7
13	Insulin-dependent translocation of the small GTP-binding protein rab3C in cardiac muscle: studies on insulin-resistant Zucker rats. *FEBS Letters*, **1995**, 377, 109-12	3.8	7
12	Erythropoietin receptors induced by dimethyl sulfoxide exhibit positive cooperativity associated with an amplified biologic response. *Proceedings of the National Academy of Sciences of the United States of America*, **1991**, 88, 2535-9	11.5	7

List of Publications

11	Novel Adenosine Analog, 6-(4-Hydroxybenzyl)-Adenosine, Dampens Alcohol Drinking and Seeking Behaviors. *Journal of Pharmacology and Experimental Therapeutics*, **2019**, 371, 260-267	4.7	7
10	Enhanced Na -K -2Cl cotransporter 1 underlies motor dysfunction in huntingtonS disease. *Movement Disorders*, **2019**, 34, 845-857	7	6
9	Supraspinal contribution to splanchnic sympathetic activity in neonatal mouse and rat brainstem-spinal cord in vitro. *Autonomic Neuroscience: Basic and Clinical*, **2010**, 156, 51-9	2.4	5
8	Type VI adenylyl cyclase negatively regulates GluN2B-mediated LTD and spatial reversal learning. *Scientific Reports*, **2016**, 6, 22529	4.9	4
7	Lack of type VI adenylyl cyclase (AC6) leads to abnormal sympathetic tone in neonatal mice. *Experimental Neurology*, **2013**, 248, 10-5	5.7	2
6	Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases. *Journal of Biomedical Science*, **2021**, 28, 70	13.3	2
5	Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy. *Acta Neuropathologica Communications*, **2021**, 9, 112	7.3	2
4	Trax: A versatile signaling protein plays key roles in synaptic plasticity and DNA repair. *Neurobiology of Learning and Memory*, **2019**, 159, 46-51	3.1	2
3	A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis.. *Movement Disorders*, **2021**,	7	2
2	Twist1 Plays an Anti-apoptotic Role in Mutant Huntingtin Expression Striatal Progenitor Cells. *Molecular Neurobiology*, **2020**, 57, 1688-1703	6.2	1
1	Amelioration of lipopolysaccharide-induced memory impairment in equilibrative nucleoside transporter-2 knockout mice is accompanied by the changes in glutamatergic pathways. *Brain, Behavior, and Immunity*, **2021**, 96, 187-199	16.6	1